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Cryptococcus neoformans is the most lethal pathogen of the central nervous system.
The gold standard treatment of cryptococcosis, a combination of amphotericin B
with 5-fluorocytosine, involves broad toxicity, high costs, low efficacy, and limited
worldwide availability. Although the need for new antifungals is clear, drug research
and development (R&D) is costly and time-consuming. Thus, drug repurposing is an
alternative to R&D and to the currently available tools for treating fungal diseases. Here
we screened a collection of compounds approved for use in humans seeking for those
with anti-cryptococcal activity. We found that benzimidazoles consist of a broad class
of chemicals inhibiting C. neoformans growth. Mebendazole and fenbendazole were
the most efficient antifungals showing in vitro fungicidal activity. Since previous studies
showed that mebendazole reaches the brain in biologically active concentrations, this
compound was selected for further studies. Mebendazole showed antifungal activity
against phagocytized C. neoformans, affected cryptococcal biofilms profoundly and
caused marked morphological alterations in C. neoformans, including reduction of
capsular dimensions. Amphotericin B and mebendazole had additive anti-cryptococcal
effects. Mebendazole was also active against the C. neoformans sibling species,
C. gattii. To further characterize the effects of the drug a random C. gattii mutant
library was screened and indicated that the antifungal activity of mebendazole requires
previously unknown cryptococcal targets. Our results indicate that mebendazole is as a
promising prototype for the future development of anti-cryptococcal drugs.
Keywords: Cryptococcus neoformans, benzimidazoles, mebendazole, antifungal, biofilm, antifungal targets,
macrophages
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INTRODUCTION
Cryptococcus neoformans is a yeast-like pathogen that causes
expressive brain damage in immunosuppressed individuals
(Colombo and Rodrigues, 2015). The fungus reaches the lungs
of humans after inhalation of environmental cells. In the
immunosuppressed host, C. neoformans efficiently disseminates
to the brain and causes meningitis (Kwon-Chung et al.,
2014). Cryptococcal meningitis is a global problem resulting in
thousands of deaths annually (Park et al., 2009). Most cases occur
among people with HIV/AIDS. Poor and late diagnosis, limited
access to antifungals and drug resistance are directly associated
to the high fatality rate of cryptococcosis, especially in developing
countries (Rodrigues, 2016).
The standard antifungal regimen for cryptococcal meningitis
is a combination of amphotericin B with 5-fluorocytosine
(Krysan, 2015). Amphotericin B is nephrotoxic and is
intravenously administered (Sloan et al., 2009; Micallef et al.,
2015), which demands considerable medical infrastructure.
A 15-day intravenous treatment with liposomal amphotericin
B is estimated to cost from €10.000 to €20.000 in Europe
(Ostermann et al., 2014) and 5-fluorocytosine is not widely
available outside rich areas (Krysan, 2015). As an alternative,
fluconazole is frequently used, although it is associated with
poorer outcomes and relapses (Sloan et al., 2009). In South
Africa, more than 60% of people with culture-positive relapsed
disease had fluconazole resistance (Govender et al., 2011). Hence,
the need for new anticryptococcal therapies is clear. In this
context, a new class of antifungals targeting the synthesis of
fungal sphingolipids has been recently described, but its efficacy
in humans is still unknown (Mor et al., 2015).
Drug repurposing has emerged as an alternative to the
costly and time-consuming processes of drug discovery and
development (Nosengo, 2016). In the field of antifungal
development, sertraline, an anti-depressive agent, has been
reported to be an in vitro and in vivo fungicidal compound that,
in combination with amphotericin B, improves the outcome of
cryptococcosis (Zhai et al., 2012; Rhein et al., 2016). Sertraline
is now under phase III trial to determine whether adjunctive
therapy will lead to improved survival (ClinicalTrials.gov, 2016).
In this manuscript, we aimed at finding anti-cryptococcal
activity in a collection of drugs previously approved for use in
human diseases. Our results are in agreement with the notion
that benzimidazole-like compounds are interesting prototypes
for the future development of efficient anti-cryptococcal
agents interfering with fungal morphology, biofilm formation,
cellular proliferation and intracellular parasitism. This study
also supports the hypothesis that the antifungal activity of
mebendazole might involve previously unknown cellular targets.
MATERIALS AND METHODS
Strains and Growth Conditions
Strains H99 of C. neoformans (sorotype A) and R265 of C. gattii
(sorotype B) were maintained in Sabouraud’s agar. For capsule
size determination and fluorescence microscopy, fungal cells
were cultivated in a minimal medium composed of glucose
(15 mM), MgSO4 (10 mM), KH2PO4 (29.4 mM), glycine
(13 mM), and thiamine-HCl (3 µM), pH5.5 for 48 h at 37◦C with
shaking. The C. gattii mutant library was maintained in 96-well
plates containing yeast peptone-dextrose (YPD) broth with 30%
glycerol at −20◦C. The cell line J774.16 (murine macrophages)
was maintained in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% of Fetal Bovine Serum (FBS), and 1%
of penicillin-streptomycin at 37◦C in 5% CO2 atmosphere. After
four passages in culture medium, the macrophages were plated
into 96 well plates for tests of mebendazole intracellular activity.
Screening for Antifungal Activity in a
Compound Collection
The National Institutes of Health (NIH) clinical collection (NCC)
was screened for antifungal activity against C. neoformans. The
NCC consists in a small molecule repository of 727 compounds
arrayed in 96-well plates at 10 mM solution in DMSO. These
compounds are part of screening library for the NIH Roadmap
Molecular Libraries Screening Centers Network (MLSCN) and
correspond to a collection of chemically diverse compounds that
have been in phase I-III clinical trials. Each compound was first
diluted to 1 mM in DMSO and stored at −20◦C until use. For
initial screening, all compounds were used at 10 µM in 100 µl
of RPMI 1640 (two times concentrated) medium buffered with
morpholinepropanesulfonic acid (MOPS) at pH 7 containing 2%
of glucose, in 96-well plates. Final concentration of DMSO in all
samples corresponded to 1%. C. neoformans cells (104) suspended
in 100 µl of water were added to each well. The plates were
incubated at 37◦C with shaking for 48 h. The optical density at
540 nm (OD540) was recorded using the FilterMax 5 microplate
reader (Molecular Devices, Sunnyvale, CA, USA). Compounds
producing values of OD540 smaller than 0.05 after fungal growth
were selected for further studies. As further detailed in the section
“Results,” mebendazole was the NCC compound selected for
most of the analysis performed in this study.
Analysis of Antifungal Activity of NCC
Compounds
Values of minimum inhibitory concentrations (MICs) were
determined using the methods proposed by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
with minor modifications. NCC compounds showing antifungal
activity were serially diluted (20 to 0.03 µM) in RPMI 1640
(two times concentrated, pH 7; 2% glucose) buffered with
MOPS in 96-well plates. The inocula of C. neoformans (strain
H99) and C. gattii (strain R265) were prepared following the
EUCAST protocol (Subcommittee on Antifungal Susceptibility
Testing of the EECfAST, 2008; Arendrup et al., 2012). The
plates were incubated at 37◦C with shaking for 48 h. MIC
values corresponded to the lowest compound concentration
producing inhibition of fungal growth. For determination of
fungicidal activity, C. neoformans cells were grown overnight
in YPD broth at 30◦C, washed in PBS and suspended in
RPMI 1640 buffered with MOPS, pH 7. The yeast suspension
was adjusted to 2 × 104 cells per 10 ml of RPMI 1640 (pH
Frontiers in Microbiology | www.frontiersin.org 2 March 2017 | Volume 8 | Article 535
fmicb-08-00535 March 25, 2017 Time: 20:3 # 3
Joffe et al. Anticryptococcal Activity of Mebendazole
7; 2% glucose) buffered with MOPS and supplemented with
1.25, 0.3125, and 0.078 µM of antifungal compounds. Final
concentration of DMSO corresponded to 0.6% in all samples.
The samples were then incubated at 37◦C in a rotary shaker
at 200 rpm. Aliquots were taken at different time points and
plated onto YPD agar plates that were incubated at 37◦C for
48 h. The numbers of CFU were then counted and recorded. The
minimum fungicidal concentration (MFC) was defined as the
lowest drug concentration inhibiting CFU formation in at least
90% in comparison to systems containing no antifungals.
Antifungal Activity of Mebendazole
against Intracellular Cryptococci
To assess antifungal activity against intracellular C. neoformans,
the fungus was first opsonized by incubation (20 min, 37◦C,
with shaking) in DMEM containing 10% FBS and 10 µg/ml
of the 18B7 IgG1, an opsonic monoclonal antibody to GXM
(Casadevall et al., 1998) kindly donated by Dr. Arturo Casadevall
(Johns Hopkins University). The fungus was washed with
fresh DMEM and incubated with J774.16 macrophages (1:1
ratio, 5 × 105 cells/well of 96 well-plates) for 2 h in
DMEM containing 10% FBS, 0.3 µg/ml LPS and 0.005 µg/ml
IFNγ (37◦C, 5% CO2). After interaction of C. neoformans
with macrophages, the systems were washed with DMEM to
remove extracellular fungal cells and fresh DMEM containing
10% FBS and variable concentrations of mebendazole (0.25,
0.5, and 1 µM, 200 µl/well) was added to each well. The
plates were incubated at 37◦C with 5% CO2. After 8 or
24 h, supernatants were collected for inoculation of YPD agar
plates and subsequent CFU counting. Alternatively, infected
macrophages were lysed with cold, distillated water and the
resulting lysates were plated onto YPD agar plates for CFU
counting. To evaluate the toxicity of mebendazole for J774.16
macrophages, 5 × 105 macrophages suspended in DMEM
containing 10% FBS were plated in each well of 96 wells
plates and incubated overnight at 37◦C with 5% CO2. The
medium was supplemented with fresh DMEM containing 10%
FBS and mebendazole (0.25, 0.5, and 1 µM) or 0.5% DMSO.
The plate was incubated at 37◦C in a 5% CO2 atmosphere.
After 48 h, the systems were washed with DMEM and 50 µl
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) at 5 mg/ml was added to each well, for further incubation
for 4 h (37◦C, 5% CO2) under light protection (Mosmann, 1983).
Supernatants were removed and 200 µl DMSO was added for
dissolution of formazan crystals. Absorbances were recorded
using the FilterMax 5 microplate reader (Molecular Devices,
Sunnyvale, CA, USA) at 570 nm.
Analysis of Synergistic Effects
Synergistic activity between mebendazole and standard
antifungal drugs was determined on the basis of the calculation
of the fractional inhibitory index (FIC) (Mor et al., 2015).
Briefly, mebendazole (denominated drug A) was serially diluted
(0.38–0.006 µg/ml, 8 dilutions) in 96-well plates. Standard
antifungals (denominated drugs B) were serially diluted
(11 dilutions) from 16 to 0.015 µg/ml (amphotericin B) or 64 to
0.06 µg/ml (fluconazole). The FIC was defined as:
MIC combined
MIC drug A alone
+ MIC combined
MIC drug B alone
Synergism was categorized as follows: strongly synergistic effect,
FIC < 0.5; synergistic effect, FIC < 1; additive effect, FIC= 1; no
effect, 1 < FIC < 2; antagonistic effect, FIC > 2 (Mor et al., 2015).
Effects of Mebendazole on
Glucuronoxylomannan (GXM) Release
Cryptococcus neoformans cells (105/well of 96-well plates, final
volume of 200 µl, duplicates) were cultivated in RPMI 1640
buffered with MOPS, pH 7. The medium was supplemented with
mebendazole (0.3125–0.001 µM). After 48 h of incubation at
37◦C with shaking, the optical density of 540 nm (OD540) was
recorded using the FilterMax 5 microplate reader (Molecular
Devices, Sunnyvale, CA, USA). The plate was centrifuged for
10 min and supernatants were used for GXM quantification by
ELISA using the protocol described by Casadevall et al. (1992).
C. neoformans viability was monitored by propidium iodide (PI)
staining of fungal cells. For this analysis, fungal cells obtained
after exposure to 0.3125, 0.15625, and 0.078 µM mebendazole
as described above were stained with 1 mg/ml PI for 5 min
on ice and analyzed by flow cytometry in a FACS Cabibur (BD
Biosciences, CA, USA). The percentage of stained (non-viable)
cells was obtained with the FlowJo 7 software.
Analysis of Capsular Size and
Morphology
Cryptococcus neoformans was grown overnight in YPD broth
and washed twice with PBS. The fungus was then suspended
in minimal medium containing sub-inhibitory concentrations
of mebendazole and incubated for 48 h at 37◦C with shaking.
C. neoformans cells were collected by centrifugation, washed
in PBS and analyzed by microscopic approaches. For capsule
size determination, the suspension was counterstained with
India ink and placed onto glass slides. The suspensions were
covered with glass coverslips and analyzed with an Axioplan 2
(Zeiss, Germany) microscope. Capsule size, calculated with
the ImageJ Software, was defined as the distance between the
cell wall and the outer border of the capsule. Cell diameters
were determined using the same software. For additional
analysis of capsular morphology, cellular suspensions were
processed for fluorescence microscopy. Staining reagents used
in this analysis-included calcofluor white (cell wall chitin, blue
fluorescence) and the monoclonal antibody 18B7 (Casadevall
et al., 1998). C. neoformans cells were prepared for fluorescence
microscopy following the protocols established by our laboratory
for routinely analysis of surface architecture (Rodrigues et al.,
2008).
Effects of Mebendazole on
C. neoformans Biofilms
Cryptococcus neoformans was grown in Sabouraud’s dextrose
broth for 24 h at 30◦C with shaking. The cells were centrifuged
at 3,000 g for 5 min, washed twice with PBS, suspended in
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minimal medium and adjusted to a density of 107 cells/ml.
Cell suspensions (100 µl) were added into quadruplicate wells
of polystyrene 96-well plates (Greiner Bio-One, Australia),
following incubation at 37◦C for 48 h. The wells containing
biofilms were washed three times with PBS to remove non-
adhered cryptococcal cells. Fungal cells that remained attached
to the wells were considered mature biofilms. To evaluate the
susceptibility of C. neoformans biofilms to mebendazole, 100 µl
solutions (31.25, 15.63, 3.13, 1.56, 0.31, and 0.16 µM) were
added to each well. Amphotericin B and fluconazole (2 and
8 µg/ml, respectively) were used as control systems of antifungal
activity. Negative controls corresponded to wells containing only
water and untreated biofilms. Mature biofilms and antifungal
drugs were incubated at 37◦C for 24 h, washed three times
with PBS and the biofilm metabolic activity quantified by the
2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)
carbonyl]-2H-tetrazolium hydroxide (XTT) reduction assay
(Meshulam et al., 1995). Prior studies demonstrated that the
XTT reduction assay measurements correlate with biofilm
and fungal cell number (Martinez and Casadevall, 2007). In
addition to testing the effects of mebendazole on established
biofilms, we evaluated whether this compound would inhibit
biofilm formation. Cryptococcal cells were suspended in
minimal medium and adjusted to a density of 107 cells/ml
in the presence or absence of mebendazole (31.25, 15.63,
3.13, 1.56, 0.31, and 0.16 µM). These suspensions were
added in quadruplicates to the wells of polystyrene 96-well
plates, following incubation at 37◦C for 48 h. Amphotericin
B and fluconazole (2 and 8 µg/ml, respectively) were used
as antifungal controls. In negative controls, wells contained
only ultrapure water. The wells were washed three times
with PBS and biofilm formation was quantified by the XTT
assay.
Analysis of the Antifungal Activity of
Mebendazole against a Collection of
C. gattii Mutants
A collection of randomly generated C. gattii mutants was
screened for identification of possible cellular targets for
antifungal activity. Mutants (n = 7,569) were generated by
insertional mutagenesis after incubation of C. gattii with
Agrobacterium tumefaciens as previously described (Idnurm
et al., 2004). All colonies that grew on YPD hygromycin
plates were selected and maintained at −20◦C in 96 wells
plates containing 200 µl/well of YPD broth. Before exposure
to mebendazole, mutant cells were first grown for 72 h (30◦C)
in 200 µl of YPD distributed into the wells of 96 wells plates.
The antifungal activity of mebendazole against C. neoformans
was reproduced in the C. gattii R265 strain. The mutants were
tested for their ability to grow in the presence of RPMI 1640
supplemented with MOPS, 2% of glucose, 1% DMSO and 10 µM
mebendazole. Resistance phenotypes (A540 > 0.3) were selected
for dose-response tests of antifungal activity as described above
and potential target identification was performed as detailed
below.
Identification of Potential Cellular
Targets Required for the Antifungal
Activity of Mebendazole
Based on clear resistant phenotypes, two C. gattii mutant
strains were selected for target identification by polymerase
FIGURE 1 | Identification of small-molecule inhibitors of Cryptococcus neoformans via drug-repurposing screening. Out of 727 compounds tested, 17
molecules induced A540 values smaller than 0.05 (dotted line). Compounds with no antifungal activity are not shown. For description of the primary activity of each
molecule, see section “Results.” Data illustrate a representative experiment of two independent screenings.
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FIGURE 2 | Dose-response curves of the antifungal effects of benzimidazoles against C. neoformans. Curves represent C. neoformans growth in
comparison with vehicle-treated cells (DMSO). Data illustrate a representative experiment of three independent replicates.
chain reaction (PCR). The fungus was cultivated overnight in
10 ml YPD at 30◦C with constant rotation. Each culture (2 ml)
was centrifuged for 2 min at 4,000 × g and cell pellets were
washed twice with PBS and collected for DNA extraction (Bolano
et al., 2001). The cells were suspended in 400 µl of lysis buffer
(50 mM Tris-HCl 1 mM EDTA, 200 mM NaCl, 2% Triton
X100, 0.5% SDS, pH 7.5), for further addition of 1 volume of
a phenol-chloroform mixture (pH 8) and 100 µl of 2-µm, acid
washed glass beads. Mechanical disruption was performed by
alternate 1-min cycles of vortexing and ice incubation. Lysates
were centrifuged 4,000× g for 20 min at 4◦C. Supernatants were
collected and DNA was ethanol-precipitated overnight at−20◦C
for subsequent treatment with RNAse (Bolano et al., 2001).
Identification of missing genes in the mutants was performed
using inverse PCR (Pavlopoulos, 2011). DNA was quantified
using the Qubit reagent (Invitrogen) and 1 µg of each sample was
cleaved separately with BglII, SalI, or StuI (Promega) restriction
enzymes. The cleavage product was submitted to T4 DNA ligase
reaction (New England) followed by PCR using primers for
inverse PCR. Amplicons were gel-purified with the QIAquick
Gel Extraction Kit (Qiagen). For the DNA sequencing reaction,
50 ng of each sample and 5 pmol of each primer were used.
Sequences were obtained in an ABI-Prism 3500 Genetic Analyzer
(Applied Biosystems) and their qualities were determined by a
electropherogram analysis based on phred1. The identification of
genes interrupted by the T-DNA was performed by comparison
of each sequenced DNA fragment, which correspond to the
T-DNA flanks, with the genomic sequence of C. neoformans H99
strain, available in the Cryptococcus genome databases (Broad
1http://www.biomol.unb.br/phph/
Institute2) using BLASTn. Orthologs distribution was evaluated
using the OrthoMCL database (Chen et al., 2006).
Mutants showing resistance to mebendazole were analyzed
for their ability to produce melanin and extracellular GXM as
previously described by our group (Rodrigues et al., 2015).
Statistical Analyses
Statistics were obtained with the GraphPad Prism 6.0 software.
Unpaired t student test was used for mebendazole toxicity
analysis. The variance two-way ANOVA was carried out using
Tukey’s and Bonferroni’s comparisons test for fungicidal activity
and intracellular activity of mebendazole in macrophages.
For biofilm analyses, one-way ANOVA was performed using
Dunnett’s multiple comparisons.
RESULTS
Selection of Mebendazole as a Potential
Anti-cryptococcal Agent
Of the 727 drugs tested at 10 µM, 17 compounds were
active against C. neoformans, including antibacterials
(chloroxine, cycloserine, and linezolid), a neuroleptic drug
(mezoridazine), calcium channel blockers (nisoldipine and
enalaprilat), antiarrhythmic agents (flecainide acetate), drugs
for gastrointestinal malignances (irsogladine maleate and
cisapride), gynecologic regulators (medroxyprogesterone
acetate and clomid), an anti-histaminic (olopatadine) and the
2http://www.broadinstitute.org/scientific-community/science/projects/fungal-
genome-initiative/cryptococcus-gattii-genome-project-0
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anti-helminthic benzimidazoles (mebendazole, albendazole,
flubendazole, and triclabendazole) (Figure 1). Noteworthy, none
of the molecules showing antifungal activity were structurally
related, except the benzimidazoles. Considering the currently
observed efficacy in inhibiting the growth of C. neoformans, their
structural similarity and previously described anti-cryptococcal
activity (Cruz et al., 1994), we selected benzimidazoles for further
investigation in our model.
We extended the results obtained with the compound
collection to dose-response tests using the four benzimidazoles
showing antifungal activity and other related molecules,
including thiabendazole, oxibendazole, and fenbendazole. The
most active compounds were mebendazole, fenbendazole,
and flubendazole (Figure 2). Mebendazole and flubendazole
produced the same MIC values (0.3125 µM). Fenbendazole
was the most potent compound, with a MIC corresponding
to 0.039 µM. Mebendazole, however, efficiently penetrates
the brain in animal models (Bai et al., 2015) and is in
clinical trial for the treatment of pediatric gliomas in humans
(ClinicalTrials.gov, 2013). Considering that the worse clinical
outcome of cryptococcosis includes colonization of the brain,
we selected mebendazole as the molecular prototype for
our subsequent analyses of fungicidal effects, ability to kill
intracellular cryptococci, effects on fungal morphology,
interference on fungal biofilms and identification of cellular
targets.
Mebendazole Is Fungicidal against
C. neoformans
To test the fungicidal activity of mebendazole, C. neoformans was
exposed to different drug concentrations for different periods of
time. Mebendazole concentrations lower than 0.3125 µM had no
effects on C. neoformans (Figure 3). At 0.3125 µM or higher,
however, significant antifungal activity was observed after 6 to
12 h of exposure of C. neoformans to the drug. After 48 h,
mebendazole killed 100% of C. neoformans cells.
Activity of Mebendazole against
Intracellular C. neoformans
Cryptococcus neoformans is a facultative intracellular pathogen
and this characteristic likely has a negative impact on the
anti-cryptococcal treatment (Feldmesser et al., 2000). We then
evaluated the ability of mebendazole to kill intracellular fungi.
J774.16 macrophages were first infected with C. neoformans
and then the cultures were treated with mebendazole for
different periods (8 and 24 h) at variable drug concentrations
(1, 0.5, and 0.25 µM). Macrophage viability was monitored
by treating non-infected J774.16 cells with mebendazole alone
(Figure 4A). After 8 h, no differences were observed between
the viability of untreated macrophages and mebendazole-
treated cells (P > 0.1). After 24 h, macrophage viability was
affected by higher mebendazole concentrations (P = 0.0071
for 1 µM mebendazole), but no differences were observed
between untreated phagocytes and cells that were exposed to
0.25 µM mebendazole (P = 0.3225). In infected macrophages,
all mebendazole concentrations showed antifungal activity
FIGURE 3 | Fungicidal activity of mebendazole against C. neoformans.
Fungal cells were exposed to mebendazole (0.078–1.25 µM) for
periods varying from 0 to 96 h. Fungicidal activity was evident after 48 h
and required a minimum concentration of 0.3125 µM mebendazole. In
comparison to control systems (no drug), mebendazole concentrations of
0.3125 and 1.25 µM significantly affected fungal growth in all incubation
periods. All the other drug concentrations resulted in fungal growth that was
similar to that observed in the absence of mebendazole. Data illustrate a
representative experiment of three independent replicates.
against both extracellular and intracellular fungi (Figure 4B).
The concentration showing the lowest impact on macrophage
viability (0.25 µM) was efficient in killing both intracellular and
extracellular C. neoformans.
Analysis of Potential Synergism between
Mebendazole and Standard Antifungals
To evaluate whether the association of mebendazole with
amphotericin B or fluconazole results in improved anti-
cryptococcal activity, checkerboard assays were performed
for calculation of the FIC index (Table 1). We found that
mebendazole had additive activity against C. neoformans when
combined with amphotericin B. Fluconazole did not show any
improved effect in combination with mebendazole.
Mebendazole Affects Capsule Size and
Fungal Morphology
To evaluate whether mebendazole affected key cellular structures
of C. neoformans during regular growth, we cultivated the fungus
for 48 h in the presence of a sub-inhibitory concentration
(IC50; 0.22 µM) of the drug for further analysis of morphology
and capsule size by a combination of fluorescence microscopy
and India ink counterstaining. Fungal cells cultivated in the
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FIGURE 4 | Activity of mebendazole against intracellular C. neoformans. (A) Viability of drug-treated, non-infected macrophages. After 8 h, all systems had
similar viability levels (P > 0.1). After 24 h, cell viability was only affected by 1 µM mebendazole concentration (P = 0.0071). (B) Activity of mebendazole against
intracellular (red bars) or extracellular (blue bars) C. neoformans. In intracellular assays, statistical differences (P < 0.05) between no drug (0) and drug-treated
systems were always observed, except when the 0.25 µM concentration of mebendazole was used in the 8 h incubation period. In extracellular assays, statistical
differences (P < 0.05) between no drug (0) and drug-treated systems were observed for all mebendazole concentrations, but only after the 24 h incubation.
Comparative analysis of fungal loads obtained from intracellular and extracellular assays revealed statistical differences (P < 0.05) only in the 8 h period of incubation,
suggesting that mebendazole is initially more effective against extracellular fungi, but similarly active against both intracellular and extracellular cryptococci after
prolonged (24 h) periods of exposure to infected macrophages. Data illustrate a representative experiment of three independent replicates.
TABLE 1 | Impact of the association of mebendazole with amphotericin B (AmB) or fluconazole (FLC) on antifungal activity.
Drug A Drug B FIC∗
MIC Alone (µg/ml) MIC Combined (µg/ml) MIC Alone (µg/ml) MIC Combined (µg/ml)
Mebendazole 0.095 0.0475 AmB 0.25 0.125 1
Mebendazole 0.095 0.0475 Fluconazole 2 2 1.5
∗Fractional inhibitory concentration index (FIC); Strongly synergistic: FIC < 0.5; Synergistic: FIC < 1; Additive: FIC = 1; No effect: 1 < FIC < 2; Antagonistic: FIC > 2.
presence of mebendazole presented marked morphological
alterations, including loss of spherical shape, intracellular furrows
(Figure 5A) and reduced capsular dimensions (Figure 5B,
P < 0.05).
Effect of Mebendazole on GXM Release
Since mebendazole interfered with capsule size (Figure 5B),
we asked whether GXM release was affected by exposure
of C. neoformans to the drug. Supernatants of fungal cells
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FIGURE 5 | Morphological alterations of C. neoformans cells treated with mebendazole. (A) India ink counterstaining (left panels) and fluorescence
microscopy (right panels) showing GXM (green fluorescence) and chitin (blue fluorescence) detection. Scale bar represents 10 µm. (B) Capsule measurement of
India ink counterstained cells showing reduction in capsular dimensions by mebendazole. Data illustrate a representative experiment of three independent replicates.
FIGURE 6 | Extracellular release of GXM by C. neoformans cells
treated with different concentrations of mebendazole. GXM extracellular
detection correlated with increasing mebendazole concentrations. Staining of
fungal cells with PI after exposure to fungicidal doses of mebendazole
revealed a similar profile, suggesting polysaccharide leakage. Data illustrate a
representative experiment of three independent replicates.
cultivated in the presence of mebendazole were used for GXM
quantification by ELISA (Figure 6). Unexpectedly, supernatants
of mebendazole-treated cells had increased GXM concentration,
mainly in the dose range required for fungal killing. Since
the polysaccharide is synthesized intracellularly (Yoneda and
Doering, 2006), we hypothesized that the increased GXM
detection would result from leakage induced by membrane
damage. To address this possibility, mebendazole-treated cells
were stained with PI. Stained cells varied from 70 to 90% in
the dose range generating cell death, which was compatible with
membrane damage and polysaccharide leakage. Noteworthy,
these results and those described in Figure 5 are also compatible
with the hypothesis of GXM release from the cell surface, so
we cannot rule out the possibility that mebendazole promotes
detachment of capsular structures in C. neoformans.
Activity of Mebendazole against
C. neoformans Biofilms
Biofilm formation causes well-known difficulties in the treatment
of a number of infectious diseases, including cryptococcosis
(Martinez and Casadevall, 2006; Borghi et al., 2016). Based
on this observation, we evaluated whether co-incubation of
mebendazole with yeast cells prevented C. neoformans biofilm
formation or caused damage to mature biofilms. The metabolic
activity was measured by XTT reduction assay (Figure 7).
Fluconazole is known to have no effects on mature biofilms,
in contrast to amphotericin B (Martinez and Casadevall, 2006).
Therefore, these drugs were used as negative and positive
controls, respectively. Mebendazole at MIC (0.3125 µM) affected
biofilm formation (Figure 7A; P < 0.0001) and damaged mature
biofilms (Figure 7B; P < 0.0001). Lower concentrations of
mebendazole similarly affected C. neoformans mature biofilms
(Figure 7B; P < 0.0001). As expected, higher concentrations
of mebendazole had even clearer impacts on C. neoformans
biofilms.
Identification of Potential Cellular
Targets for Mebendazole
Antifungal activities of benzimidazoles were described before
(Cruz et al., 1994), but the mechanisms by which these drugs
affected cryptococcal growth remained unknown. In order to
identify potential targets for mebendazole in Cryptococcus spp.,
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FIGURE 7 | Effects of mebendazole on cryptococcal biofilms. Biofilm formation and mature biofilm activity were measured indirectly by XTT reduction assay.
(A) Incubation of C. neformans with mebendazole before biofilm formation. (B) Treatment of mature biofilms with mebendazole. AmB, amphotericin B (2 µg/ml);
Fluco, fluconazole (8 µg/ml). Statistical significances after comparison with control systems are indicated by asterisks (P < 0.0001). Data illustrate a representative
experiment of three independent replicates.
we first evaluated whether the drug affected the growth of C. gattii
and C. neoformans in a similar fashion. In fact, growth inhibition
curves were identical for both pathogens (Figure 8A).
A mutant collection generated by co-incubation of C. gattii
and A. tumefaciens (Idnurm et al., 2004) was produced by our
group for general purposes involving development of antifungals
and pathogenic studies. In the present study, these mutants
were screened for resistance phenotypes in the presence of
10 µM mebendazole, based on the assumption that, in the
absence of a cellular target required for antifungal activity,
the drug would lack anti-cryptococcal properties. Most of
the mutants were sensitive to mebendazole and a number
of strains were partially resistant to the drug (Figure 8B).
However, two of the mutant strains clearly stood out from the
entire collection, showing highest levels of resistance even in
higher mebendazole concentrations (Figure 8C). Interrupted
regions in these two mutants were identified by inverse PCR
(Figure 8D). In the most mebendazole-resistant mutant, the
protein codified by the interrupted gene contained a scramblase
domain (PF03803 – CNBG_3981). In the second most resistant
mutant, the gene coding for ribosome biogenesis protein Nop16
(PF09420 – CNBG_3695) was interrupted. These domains were
found in diverse phylogenetic groups, according to the PFAM
database (Finn et al., 2016). However, orthologs for these genes
were found in a narrow group of organisms and absent in human
cells (Figure 8D), according to OrthoMCL database (Chen et al.,
2006). These results indicate that at least two novel cellular targets
are involved in the antifungal activity of mebendazole.
Neutralizing cryptococcal virulence factors is also likely to
be beneficial for the control of cryptococcosis. In this context,
we evaluated whether the mutants lacking potential targets for
activity of mebendazole had normal production of the most-well
characterized cryptococcal virulence factors. The two mutants
had normal urease activity (not shown). Analysis of extracellular
GXM and pigmentation, however, showed important differences
between WT and mutant cells (Figure 9). Mutants disrupted for
expression of the putative scramblase and of nucleolar protein 16
had decreased contents of extracellular GXM, in comparison with
WT cells (P < 0.001). The kinetics of melanin production was
also negatively affected in the mutants.
DISCUSSION
Processes of drug research and development are costly, time
consuming and have questionable success (Kaitin, 2010; Kaitin
and DiMasi, 2011). In this scenario, drug repurposing has
provided a potential boost to the drug pipeline combating
health emergencies and assisting neglected populations. Recent
studies have provided evidence of successful drug repurposing
to combat Cryptococcus (ClinicalTrials.gov, 2016; Rhein et al.,
2016) and Zika virus (Veljkovic and Paessler, 2016; Xu et al.,
2016; Sacramento et al., 2017) infections with promising results.
The need for additional anti-infectious agents, however, is
clear.
In this study, we identified small-molecule inhibitors
of C. neoformans via a drug-repurposing screen. Our
findings demonstrated antifungal activity in a group of
anti-helminthic benzimidazoles and suggested potential targets
for development of novel antifungals. Benzimidazoles are
heterocyclic aromatic bis-nitrogen azoles that are considered
promising anchors for development of new therapeutic
agents (Bansal and Silakari, 2012). Benzimidazole derivatives
have been associated to the control of infectious diseases
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FIGURE 8 | Potential cellular targets required for mebendazole activity. (A) Comparative analysis showing that C. neoformans and C. gattii are similarly
susceptible to mebendazole. (B) Screening of a C. gattii mutant library in the presence of 10 µM of mebendazole, revealing two highly resistant strains (arrows).
(C) Growth of the two mutants selected in panel B in the presence of variable concentrations of mebendazole. (D) Sequence identification by PCR and distribution of
cellular proteins required for mebendazole activity.
through antiviral, antifungal, antimicrobial, and antiprotozoal
properties, but they also manifest antiinflammatory, anticancer,
antioxidant, anticoagulant, antidiabetic and antihypertensive
activities (Ates-Alagoz, 2016). The anti-cryptococcal activity of
benzimidazoles was demonstrated two decades ago (Cruz et al.,
1994), but the effects of these compounds on fungal morphology
and biofilm formation were not explored. Similarly, their
cellular targets and ability to kill intracellular fungi remained
unknown. Mebendazole, one of the benzimidazoles showing
antifungal activity, is in clinical trial for the treatment of human
pediatric glioma (ClinicalTrials.gov, 2013). Since effective
anti-cryptococcal agents obligatorily need to reach the central
nervous system at biologically active concentrations, we selected
mebendazole for our experiments of antifungal activity. This
compound affected cryptococcal growth, morphology, biofilms
and macrophage infection.
The pathogenic mechanisms used by C. neoformans during
infection bring significant complexities in the management
of cryptococcosis. Conditions favoring biofilm formation are
thought to contribute to cryptococcal virulence (Benaducci et al.,
2016). Like with other pathogens, C. neoformans biofilms are
resistant to antimicrobial agents and host defense mechanisms,
causing significant morbidity and mortality (Martinez and
Casadevall, 2015). These characteristics are especially relevant
in a scenario of increasing use of ventriculoperitoneal shunts to
manage intracranial hypertension associated with cryptococcal
meningoencephalitis (Martinez and Casadevall, 2015). In
our model, mebendazole was an efficient antifungal agent
against C. neoformans biofilms. The minimum mebendazole
concentration required for antifungal activity against planktonic
cells (0.325 µM) was much higher than the doses required for
activity against mature biofilms (0.0156–0.0312 µM). The reason
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FIGURE 9 | Cryptococcus gattii mutants lacking potential targets for mebendazole activity show defective capacity to produce well-known
cryptococcal virulence factors. GXM determination by ELISA (left panel) indicated that the putative scramblase and nucleolar protein 16 were required for
polysaccharide export. Both proteins were apparently involved in the kinetics of pigmentation in C. gattii (right panel).
for this discrepancy is unclear. Since capsular polysaccharides
have well described roles on the assembly of cryptococcal biofilms
(Martinez and Casadevall, 2005), we hypothesize that the herein
described impact of mebendazole on capsular architecture and
GXM release may affect biofilm stability.
An additional complexity in the treatment of cryptococcosis
is the ability of the fungus to reside inside phagocytes. In
fact, persistent pulmonary infection is associated with the
intracellular parasitism of C. neoformans (Goldman et al.,
2000). In this context, targeting intracellular survival and
growth and/or cryptococcal virulence factors expressed during
intracellular parasitism might offer new strategies to improve
anticryptococcal treatment, as reviewed by Voelz and May
(2010). Mebendazole was effective against phagocytized fungi
in our model. The fact that the anti-helminthic compound had
an additive effect to AmB also suggests that benzimidazole-
like compounds could be used in therapeutic protocols against
cryptococcosis.
The primary mechanism of anthelmintic activity of
mebendazole relies on binding the β-subunit of tubulin
before dimerization with α-tubulin, with subsequent blocking
of microtubule formation (Gardner and Hill, 2001). Tubulin
may also be the target of mebendazole in C. neoformans, but
our studies suggest the possibility that the antifungal effects
of mebendazole may involve additional targets. Mebendazole
induced membrane permeabilization, as concluded from
increased levels of PI staining after exposure of C. neoformans
to the drug. In addition, mutants lacking genes coding for
a putative scramblase and the nucleolar protein Nop16
were highly resistant to mebendazole. Both mutants had
defective formation of important virulence factors. Remarkably,
sequences showing similarity to these two proteins were
absent in human cells, suggesting a great potential for these
two proteins as novel antifungal specific targets. Scramblases
are ATP-independent enzymes that act to randomize lipid
distribution by bidirectionally translocating lipids between
leaflets (Hankins et al., 2015). Lipid-translocating enzymes,
in fact, are fundamental for cryptococcal pathogenesis and
GXM export (Hu and Kronstad, 2010; Rizzo et al., 2014).
The functions of Nop16 in C. neoformans are unknown,
but in S. cerevisiae this protein is a component of 66S
pre-ribosomal particles required for 60S ribosomal subunit
biogenesis (Harnpicharnchai et al., 2001; Horsey et al., 2004).
Although there is no evidence in the literature linking tubulin
polymerization, membrane permeability and cellular functions of
these two potential targets, our studies suggest that a connection
may exist and these proteins may be functionally integrated in
fungi.
Cryptococcosis affects regions where health infrastructure
resources are extremely limited. Considering the high mortality
rates associated with this disease and the socio-economic
scenario behind cryptococcosis, low-cost and efficient antifungal
alternatives are urgent. Clinical use of novel drugs, however,
depends on a number of properties of the molecular candidates.
In this regard, the potential use of mebendazole against human
cryptococcosis raises several concerns. For instance, the use of
mebendazole at large doses may cause bone marrow suppression
(Fernandez-Banares et al., 1986) and it is unclear if the
compound is safe in pregnancy (Torp-Pedersen et al., 2012).
Benzimidazoles have only limited water solubility, which impacts
the rate and extent of their absorption and, consequently,
systemic bioavailability, maximal plasma concentration, and
tissue distribution (McKellar and Scott, 1990). Animal studies
with mebendazole demonstrated drug distribution through all
the organs, including the central nervous system (Lanusse and
Prichard, 1993). However, the drug and its metabolites were
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concentrated mainly in the liver, where they remain for at
least 15 days post treatment (Lanusse and Prichard, 1993).
Mebendazole is thought to be the active form of the drug
rather than its metabolites (Gottschall et al., 1990). However, in
the liver, benzimidazoles are mostly modified by the enzymatic
system of hepatic microsomal oxidases, which are involved in
sulfoxidation, demethylation, and hydroxylation (Short et al.,
1988; Lanusse and Prichard, 1993). In fact, benzimidazoles
are usually short lived and metabolic products predominate in
plasma and all tissues and excreta of the host (Fetterer and Rew,
1984).
Although the difficulties associated with the clinical use of
mebendazole are clear, our results combine a multiple antifungal
activity with molecular targets that are absent in human
cells, which encourages further development of benzimidazole-
like molecules against C. neoformans. In fact, a number of
reports have suggested that the benzimidazole core represents
a promising scaffold for development of new therapeutic
agents (Yadav and Ganguly, 2015). Montresor et al. (2010)
estimated that the cost to procure one million doses of standard
benzimidazoles (500 mg each) would be approximately US$
20,000, including international transport. In this context, the
ability of mebendazole to penetrate the brain (Bai et al., 2015)
and to cause expressive damage in C. neoformans cells suggest
great potential as a prototype for development of novel anti-
cryptococcal agents.
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